JP2011172579A5 - - Google Patents

Download PDF

Info

Publication number
JP2011172579A5
JP2011172579A5 JP2011083817A JP2011083817A JP2011172579A5 JP 2011172579 A5 JP2011172579 A5 JP 2011172579A5 JP 2011083817 A JP2011083817 A JP 2011083817A JP 2011083817 A JP2011083817 A JP 2011083817A JP 2011172579 A5 JP2011172579 A5 JP 2011172579A5
Authority
JP
Japan
Prior art keywords
present
dtdt
seq
consecutive
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011083817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011172579A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011172579A publication Critical patent/JP2011172579A/ja
Publication of JP2011172579A5 publication Critical patent/JP2011172579A5/ja
Pending legal-status Critical Current

Links

JP2011083817A 2004-01-30 2011-04-05 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法 Pending JP2011172579A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54068704P 2004-01-30 2004-01-30
US60/540,687 2004-01-30
US64152205P 2005-01-04 2005-01-04
US60/641,522 2005-01-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006550491A Division JP4755113B2 (ja) 2004-01-30 2005-01-27 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2011172579A JP2011172579A (ja) 2011-09-08
JP2011172579A5 true JP2011172579A5 (cg-RX-API-DMAC7.html) 2012-07-05

Family

ID=34830511

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006550491A Expired - Fee Related JP4755113B2 (ja) 2004-01-30 2005-01-27 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法
JP2011083817A Pending JP2011172579A (ja) 2004-01-30 2011-04-05 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006550491A Expired - Fee Related JP4755113B2 (ja) 2004-01-30 2005-01-27 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法

Country Status (6)

Country Link
US (3) US20050197310A1 (cg-RX-API-DMAC7.html)
EP (2) EP1758998B1 (cg-RX-API-DMAC7.html)
JP (2) JP4755113B2 (cg-RX-API-DMAC7.html)
AT (1) ATE491715T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005025347D1 (cg-RX-API-DMAC7.html)
WO (1) WO2005072057A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4755113B2 (ja) * 2004-01-30 2011-08-24 クアーク・ファーマスーティカルス、インコーポレイテッド 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法
US20100266574A1 (en) * 2005-06-10 2010-10-21 Orna Mor Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases
WO2008063760A2 (en) * 2006-10-18 2008-05-29 The University Of Texas M.D. Anderson Cancer Center Methods for treating cancer targeting transglutaminase
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のsiRNAおよびその使用方法
US20100273854A1 (en) * 2007-06-15 2010-10-28 Hagar Kalinski Compositions and methods for inhibiting nadph oxidase expression
WO2009132351A2 (en) * 2008-04-25 2009-10-29 University Of Medicine And Dentistry Of New Jersey Anti-sense microrna expression vectors
SG192648A1 (en) * 2011-02-09 2013-09-30 Singapore Health Serv Pte Ltd Transglutaminase-2 inhibitors and uses thereof
US9580708B2 (en) * 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
WO2013110005A1 (en) 2012-01-18 2013-07-25 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
WO2013142514A1 (en) * 2012-03-19 2013-09-26 Isis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
EP2895200B1 (en) 2012-09-14 2019-11-06 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
US10155948B2 (en) 2016-05-12 2018-12-18 Kangwon National University University-Industry Cooperation Foundation and Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications
KR101881662B1 (ko) * 2016-05-12 2018-07-26 강원대학교산학협력단 당뇨성 합병증 예방 및 치료용 약제학적 조성물 및 당뇨성 합병증 예방 또는 치료제 스크리닝 방법
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
IT201800009133A1 (it) * 2018-10-03 2020-04-03 Università Cattolica del Sacro Cuore Identificazione di biomarcatori molecolari predittivi di risposta al trattamento radiochemoterapico nel carcinoma della cervice
WO2023201362A2 (en) * 2022-04-14 2023-10-19 Aro Biotherapeutics Company Fn3 domain-sirna conjugates with enzyme replacement therapy

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5270030A (en) 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
US5021440A (en) 1989-07-31 1991-06-04 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5098707A (en) 1989-07-31 1992-03-24 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US4968713A (en) 1989-07-31 1990-11-06 Merck & Co., Inc. Certain imidazole compounds as transglutaminase inhibitors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
AU662298B2 (en) 1990-09-20 1995-08-31 Gilead Sciences, Inc. Modified internucleoside linkages
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
WO1993023569A1 (en) 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
AU6620596A (en) * 1996-07-25 1998-02-20 Victoria University Of Manchester, The Use of transglutaminase modulators to promote wound healing
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
CA2347905C (en) 1998-10-26 2009-12-15 Avi Biopharma, Inc. P53 antisense agent and method
ATE330631T1 (de) * 1999-01-05 2006-07-15 Univ Southern Australia Antikörperfragmente zur lokalen behandlung von augenerkrankungen
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
AU2001249622B2 (en) * 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
EP1873259B1 (en) * 2000-12-01 2012-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediated by 21 and 22nt RNAs
US20070021360A1 (en) * 2001-04-24 2007-01-25 Nyce Jonathan W Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
AU2002305236A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
US20040019001A1 (en) 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
WO2003070197A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP3222724B1 (en) 2002-08-05 2018-10-31 Silence Therapeutics GmbH Further novel forms of interfering rna molecules
AU2003286746A1 (en) * 2002-10-29 2004-05-25 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
EP1644475A4 (en) * 2003-06-20 2009-06-03 Isis Pharmaceuticals Inc DOUBLE-STRAND COMPOSITIONS WITH A 3'-ENDO-MODIFIED STRING FOR USE IN GENE MODULATION
JP4755113B2 (ja) 2004-01-30 2011-08-24 クアーク・ファーマスーティカルス、インコーポレイテッド 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法

Similar Documents

Publication Publication Date Title
JP2011172579A5 (cg-RX-API-DMAC7.html)
JP2013539454A5 (cg-RX-API-DMAC7.html)
JP2011155981A5 (cg-RX-API-DMAC7.html)
JP2012505657A5 (cg-RX-API-DMAC7.html)
WO2013006795A3 (en) Antiviral compositions and methods of their use
JP2011168603A5 (cg-RX-API-DMAC7.html)
JP2010523596A5 (cg-RX-API-DMAC7.html)
CY1115253T1 (el) Κρυσταλλικες μορφες ενος παραγωγου 2-θειαζολυλο-4-κινολινυλ-οξυ-ομαδας, ενος ισχυρου αναστολεα του ηcv
JP2011136981A5 (cg-RX-API-DMAC7.html)
JP2009541403A5 (cg-RX-API-DMAC7.html)
WO2011139699A3 (en) 5' modified nucleosides and oligomeric compounds prepared therefrom
IL264288B (en) Methods and compositions for modulating apolipoprotein(a) expression
IL206462A0 (en) Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
JP2010088434A5 (cg-RX-API-DMAC7.html)
JP2013512915A5 (cg-RX-API-DMAC7.html)
JP2012034696A5 (cg-RX-API-DMAC7.html)
IL219865A0 (en) Acid salt forms of polymer-drug conjugates, compositions comprising the same, methods of producing the same and uses thereof
MY160722A (en) Preparing high order hydridosilane compounds
JP2015502963A5 (cg-RX-API-DMAC7.html)
JP2014521310A5 (cg-RX-API-DMAC7.html)
JP2013504665A5 (cg-RX-API-DMAC7.html)
JP2013503110A5 (cg-RX-API-DMAC7.html)
JP2015513535A5 (cg-RX-API-DMAC7.html)
JP2015128433A5 (cg-RX-API-DMAC7.html)
JP2012517503A5 (cg-RX-API-DMAC7.html)